Aurinia Pharmaceuticals Inc Stock News

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multip…

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today annou

Could both of these volatile stocks be winners in the long run?

Assenagon Asset Management S.A. acquired a new position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) during the 1st quarter, according to the company in its most recent disclosure

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (BTAI), Madrigal Pharmaceuticals

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Entasis Therapeutics Holdings (ETTX) today and set a price target of $5.00. The company's

These three developmental-stage pharma stocks are attracting some of the smartest investors right now.

Yale scientists found that transcription factor HIF-1 helps T cells adapt to an oxygen-starved environment in the kidney and contributes to inflammation and tissue damage in lupus. Treatment with a HI

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

In a report released today, Alethia Young from Cantor Fitzgerald reiterated a Buy rating on Gilead Sciences (GILD), with a price target of $86.00. The